BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $200.95 Million Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in Hologic, Inc. (NASDAQ:HOLX) by 8.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,466,888 shares of the medical equipment provider’s stock after purchasing an additional 195,285 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned approximately 1.06% of Hologic worth $200,952,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD increased its holdings in shares of Hologic by 77.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock worth $490,931,000 after buying an additional 2,753,016 shares in the last quarter. Swedbank AB acquired a new stake in shares of Hologic during the first quarter worth approximately $120,827,000. Black Creek Investment Management Inc. increased its holdings in shares of Hologic by 60.9% during the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock worth $173,669,000 after buying an additional 885,524 shares in the last quarter. Mackenzie Financial Corp increased its holdings in shares of Hologic by 1,023.3% during the second quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider’s stock worth $66,506,000 after buying an additional 815,960 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Hologic during the second quarter worth approximately $39,427,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Price Performance

Shares of HOLX stock opened at $78.04 on Thursday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. Hologic, Inc. has a 52-week low of $67.59 and a 52-week high of $84.67. The firm’s 50 day moving average price is $80.52 and its two-hundred day moving average price is $78.30. The stock has a market cap of $18.13 billion, a PE ratio of 23.44, a PEG ratio of 2.48 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same period in the previous year, the business earned $0.89 EPS. The company’s revenue was up 4.5% compared to the same quarter last year. As a group, analysts forecast that Hologic, Inc. will post 4.27 EPS for the current year.

Wall Street Analysts Forecast Growth

HOLX has been the subject of several recent analyst reports. Raymond James raised their price objective on shares of Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Evercore ISI raised their price target on shares of Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a report on Tuesday, October 1st. JPMorgan Chase & Co. raised their price target on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Royal Bank of Canada raised their price target on shares of Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a report on Tuesday, November 5th. Finally, Stephens reissued an “overweight” rating and issued a $92.00 price target on shares of Hologic in a report on Tuesday, July 30th. Four equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $89.91.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.